

# Anna Erdei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4130247/publications.pdf>

Version: 2024-02-01

135  
papers

3,720  
citations

136950

32  
h-index

161849

54  
g-index

143  
all docs

143  
docs citations

143  
times ranked

3828  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation. <i>Frontiers in Immunology</i> , 2022, 13, 845953.	4.8	11
2	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660382.	4.8	7
3	Revisiting the Coreceptor Function of Complement Receptor Type 2 (CR2, CD21); Coengagement With the B-Cell Receptor Inhibits the Activation, Proliferation, and Antibody Production of Human B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 620427.	4.8	21
4	BCR activated CLL B cells use both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) for adhesion while CR4 has a dominant role in migration towards SDF-1. <i>PLoS ONE</i> , 2021, 16, e0254853.	2.5	1
5	Robert B. Simão Tribute. <i>Viruses</i> , 2021, 13, 1681.	3.3	0
6	New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4. <i>Immunology Letters</i> , 2021, 237, 42-57.	2.5	23
7	Label-free real-time monitoring of the BCR-triggered activation of primary human B cells modulated by the simultaneous engagement of inhibitory receptors. <i>Biosensors and Bioelectronics</i> , 2021, 191, 113469.	10.1	7
8	Natural Compounds as Target Biomolecules in Cellular Adhesion and Migration: From Biomolecular Stimulation to Label-Free Discovery and Bioactivity-Based Isolation. <i>Biomedicines</i> , 2021, 9, 1781.	3.2	5
9	Activated Human Memory B Lymphocytes Use CR4 (CD11c/CD18) for Adhesion, Migration, and Proliferation. <i>Frontiers in Immunology</i> , 2020, 11, 565458.	4.8	14
10	The differential role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in the adherence, migration and podosome formation of human macrophages and dendritic cells under inflammatory conditions. <i>PLoS ONE</i> , 2020, 15, e0232432.	2.5	21
11	Utilization of complement receptors in immune cell-microbe interaction. <i>FEBS Letters</i> , 2020, 594, 2695-2713.	2.8	19
12	Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses. <i>Frontiers in Immunology</i> , 2019, 10, 1493.	4.8	10
13	Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men. <i>Seminars in Cell and Developmental Biology</i> , 2019, 85, 110-121.	5.0	64
14	The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes. <i>Immunology Letters</i> , 2017, 189, 64-72.	2.5	99
15	Label-free optical biosensor for on-line monitoring the integrated response of human B cells upon the engagement of stimulatory and inhibitory immune receptors. <i>Sensors and Actuators B: Chemical</i> , 2017, 240, 528-535.	7.8	23
16	Functional studies of chronic lymphocytic leukemia B cells expressing $\beta_2$ -integrin type complement receptors CR3 and CR4. <i>Immunology Letters</i> , 2017, 189, 73-81.	2.5	12
17	Complement Receptor Type 1 Suppresses Human B Cell Functions in SLE Patients. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	2.2	13
18	CD11c/CD18 Dominates Adhesion of Human Monocytes, Macrophages and Dendritic Cells over CD11b/CD18. <i>PLoS ONE</i> , 2016, 11, e0163120.	2.5	72

#	ARTICLE	IF	CITATIONS
19	Adhesion kinetics of human primary monocytes, dendritic cells, and macrophages: Dynamic cell adhesion measurements with a label-free optical biosensor and their comparison with end-point assays. <i>Biointerphases</i> , 2016, 11, 031001.	1.6	15
20	Regulation of B cell functions by Toll-like receptors and complement. <i>Immunology Letters</i> , 2016, 178, 37-44.	2.5	9
21	The versatile functions of complement C3a-derived ligands. <i>Immunological Reviews</i> , 2016, 274, 127-140.	6.0	34
22	Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1023-1031.	3.3	22
23	Non-CpG Oligonucleotides Exert Adjuvant Effects by Enhancing Cognate B Cell-T Cell Interactions, Leading to B Cell Activation, Differentiation, and Isotype Switching. <i>Journal of Immunology Research</i> , 2015, 2015, 1-8.	2.2	2
24	Syk is indispensable for CpG-induced activation and differentiation of human B cells. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2223-2236.	5.4	26
25	Complement receptor type 1 (CR1/CD35) expressed on activated human CD4+ T cells contributes to generation of regulatory T cells. <i>Immunology Letters</i> , 2015, 164, 117-124.	2.5	22
26	Secreted aspartic protease 2 of <i>Candida albicans</i> inactivates factor H and the macrophage factor H-receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18). <i>Immunology Letters</i> , 2015, 168, 13-21.	2.5	32
27	Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro. <i>PLoS ONE</i> , 2015, 10, e0124234.	2.5	7
28	Single Cell Adhesion Assay Using Computer Controlled Micropipette. <i>PLoS ONE</i> , 2014, 9, e111450.	2.5	30
29	Automated single cell sorting and deposition in submicroliter drops. <i>Applied Physics Letters</i> , 2014, 105, .	3.3	13
30	Coadministration of antigen-conjugated and free CpG: Effects of in vitro and in vivo interactions in a murine model. <i>Immunology Letters</i> , 2014, 160, 178-185.	2.5	6
31	EFIS: Driving women's representation in immunology in Europe. <i>European Journal of Immunology</i> , 2014, 44, 615-616.	2.9	5
32	In-situ and label-free optical monitoring of the adhesion and spreading of primary monocytes isolated from human blood: Dependence on serum concentration levels. <i>Biosensors and Bioelectronics</i> , 2014, 54, 339-344.	10.1	30
33	Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. <i>International Immunology</i> , 2013, 25, 25-33.	4.0	35
34	CR3 is the dominant phagocytotic complement receptor on human dendritic cells. <i>Immunobiology</i> , 2013, 218, 652-663.	1.9	32
35	Phosphorylation adjacent to the nuclear localization signal of human dUTPase abolishes nuclear import: structural and mechanistic insights. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 2495-2505.	2.5	42
36	Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation. <i>Immunology Letters</i> , 2012, 143, 131-136.	2.5	15

#	ARTICLE	IF	CITATIONS
37	Generation of Gene-Engineered Chimeric DNA Molecules for Specific Therapy of Autoimmune Diseases. <i>Human Gene Therapy Methods</i> , 2012, 23, 357-365.	2.1	4
38	Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarrays. <i>Journal of Immunological Methods</i> , 2012, 375, 75-83.	1.4	7
39	Impact of molecular mimicry on the clinical course and outcome of sepsis syndrome. <i>Molecular Immunology</i> , 2011, 49, 512-517.	2.2	8
40	Association of RNA with the uracilâ€DNAâ€degrading factor has major conformational effects and is potentially involved in protein folding. <i>FEBS Journal</i> , 2011, 278, 295-315.	4.7	6
41	Modulation of the humoral immune response by targeting CD40 and FcÎ³RII/III; delivery of soluble but not particulate antigen to CD40 enhances antibody responses with a Th1 bias. <i>Molecular Immunology</i> , 2011, 49, 155-162.	2.2	4
42	Cellular Response to Efficient dUTPase RNAi Silencing in Stable HeLa Cell Lines Perturbs Expression Levels of Genes Involved in Thymidylate Metabolism. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011, 30, 369-390.	1.1	21
43	Elimination of autoreactive B cells in humanized SCID mouse model of SLE. <i>European Journal of Immunology</i> , 2011, 41, 3301-3311.	2.9	18
44	Transgenic expression of bovine neonatal Fc receptor in mice boosts immune response and improves hybridoma production efficiency without any sign of autoimmunity. <i>Immunology Letters</i> , 2011, 137, 62-69.	2.5	15
45	Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies. <i>MAbs</i> , 2011, 3, 431-439.	5.2	19
46	Neonatal FcR Overexpression Boosts Humoral Immune Response in Transgenic Mice. <i>Journal of Immunology</i> , 2011, 186, 959-968.	0.8	65
47	Mucosal Immunity and the Intestinal Microbiome in the Development of Critical Illness. <i>ISRN Immunology</i> , 2011, 2011, 1-12.	0.7	3
48	Introduction. <i>Immunology Letters</i> , 2010, 130, 1.	2.5	1
49	Modulation of immune response by combined targeting of complement receptors and low-affinity FcÎ³ receptors. <i>Immunology Letters</i> , 2010, 130, 66-73.	2.5	7
50	Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice. <i>Rheumatology</i> , 2010, 49, 2273-2280.	1.9	17
51	Antigen microarrays: descriptive chemistry or functional immunomics?. <i>Trends in Immunology</i> , 2010, 31, 133-137.	6.8	28
52	Transient deplementation of mice delays onset of experimental autoimmune encephalomyelitis and impairs MOG-specific T cell response and autoantibody production. <i>Molecular Immunology</i> , 2009, 47, 57-63.	2.2	12
53	Mathematical analysis of clinical data reveals a homunculus of bacterial mimotopes protecting from autoimmunity via oral tolerance in human. <i>Molecular Immunology</i> , 2009, 46, 1673-1678.	2.2	4
54	Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. <i>Molecular Immunology</i> , 2009, 46, 2767-2773.	2.2	76

#	ARTICLE	IF	CITATIONS
55	A novel, complement-mediated way to enhance the interplay between macrophages, dendritic cells and T lymphocytes. <i>Molecular Immunology</i> , 2009, 47, 438-448.	2.2	17
56	Novel roles for murine complement receptors type 1 and 2. <i>Immunology Letters</i> , 2008, 116, 163-167.	2.5	10
57	Two-dimensional immune profiles improve antigen microarray-based characterization of humoral immunity. <i>Proteomics</i> , 2008, 8, 2840-2848.	2.2	13
58	News and EFIS - Eur. J. Immunol. 6/2008. <i>European Journal of Immunology</i> , 2008, 38, 1476-1478.	2.9	0
59	Novel roles for murine complement receptors type 1 and 2. <i>Immunology Letters</i> , 2008, 116, 156-162.	2.5	17
60	Introduction. <i>Immunology Letters</i> , 2008, 116, 103.	2.5	0
61	An antibody-based construct carrying DNA-mimotope and targeting CR1 (CD35) selectively suppresses human autoreactive B-lymphocytes. <i>Immunology Letters</i> , 2008, 116, 168-173.	2.5	28
62	Set a thief to catch a thief: Self-reactive innate lymphocytes and self tolerance. <i>Autoimmunity Reviews</i> , 2008, 7, 278-283.	5.8	11
63	B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity. <i>Molecular Immunology</i> , 2008, 45, 2343-2351.	2.2	44
64	Detection of Complement Activation on Antigen Microarrays Generates Functional Antibody Profiles and Helps Characterization of Disease-Associated Changes of the Antibody Repertoire. <i>Journal of Immunology</i> , 2008, 181, 8162-8169.	0.8	14
65	Physiological up-regulation of inhibitory receptors FcγRII and CR1 on memory B cells is lacking in SLE patients. <i>International Immunology</i> , 2008, 20, 185-192.	4.0	34
66	C3a-derived peptide binds to the type I FcγAR and inhibits proximal-coupling signal processes and cytokine secretion by mast cells. <i>International Immunology</i> , 2008, 20, 1239-1245.	4.0	8
67	On-chip Complement Activation Adds an Extra Dimension to Antigen Microarrays. <i>Molecular and Cellular Proteomics</i> , 2007, 6, 133-140.	3.8	19
68	A novel fruitfly protein under developmental control degrades uracil-DNA. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 643-648.	2.1	22
69	Complement protein C1q induces maturation of human dendritic cells. <i>Molecular Immunology</i> , 2007, 44, 3389-3397.	2.2	76
70	Altered Expression of FcγA and Complement Receptors on B Cells in Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 183-192.	3.8	8
71	The brain-specific protein TPPP/p25 in pathological protein deposits of neurodegenerative diseases. <i>Acta Neuropathologica</i> , 2007, 113, 153-161.	7.7	65
72	Murine CR1/2 Targeted Antigenized Single-Chain Antibody Fragments Induce Transient Low Affinity Antibodies and Negatively Influence an Ongoing Immune Response. , 2007, 598, 214-225.		6

#	ARTICLE	IF	CITATIONS
73	The role of CR2 in autoimmunity. <i>Autoimmunity</i> , 2006, 39, 357-366.	2.6	19
74	Interaction of TPPP/p25 protein with glyceraldehyde-3-phosphate dehydrogenase and their co-localization in Lewy bodies. <i>FEBS Letters</i> , 2006, 580, 5807-5814.	2.8	34
75	Expression and role of Fc- and complement-receptors on human dendritic cells. <i>Immunology Letters</i> , 2006, 104, 46-52.	2.5	65
76	The Role of the Complement System in the Pathogenesis of Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. , 2006, 586, 177-188.		1
77	Establishment of the "EFIS-Lecture Award". <i>Immunology Letters</i> , 2005, 100, 5.	2.5	0
78	FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene. <i>European Journal of Human Genetics</i> , 2005, 13, 321-329.	2.8	45
79	The $\beta$ Subunit of the Type I Fc $\gamma$ Receptor Is a Target for Peptides Inhibiting IgE-Mediated Secretory Response of Mast Cells. <i>Journal of Immunology</i> , 2005, 175, 2801-2806.	0.8	20
80	Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 541-547.	2.9	76
81	Developmental Regulation of dUTPase in <i>Drosophila melanogaster</i> . <i>Journal of Biological Chemistry</i> , 2004, 279, 22362-22370.	3.4	38
82	Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3). <i>J Biol Chem</i> 2004; 279: 8710-8714	0.8	87
83	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. <i>Journal of Immunology</i> , 2004, 173, 747-754.	0.8	155
84	Complement C3 and C5 play critical roles in traumatic brain injury: blocking effects on neutrophil extravasation by C5a receptor antagonist. <i>Journal of Neuroimmunology</i> , 2004, 155, 55-63.	2.3	119
85	Regulation of B-cell activation by complement receptors CR1 (CD35) and CR2 (CD21) – possible involvement in the pathogenesis of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2004, 3, 624-625.	5.8	0
86	Regulation of mast cell activation by complement-derived peptides. <i>Immunology Letters</i> , 2004, 92, 39-42.	2.5	41
87	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. <i>Molecular Immunology</i> , 2004, 40, 1213-1221.	2.2	57
88	Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. <i>Neurobiology of Disease</i> , 2004, 17, 155-162.	4.4	140
89	Targeting with scFv: immune modulation by complement receptor specific constructs. <i>Journal of Molecular Recognition</i> , 2003, 16, 318-323.	2.1	2
90	dUTPase and Nucleocapsid Polypeptides of the Mason-Pfizer Monkey Virus Form a Fusion Protein in the Virion with Homotrimeric Organization and Low Catalytic Efficiency. <i>Journal of Biological Chemistry</i> , 2003, 278, 38803-38812.	3.4	21

#	ARTICLE	IF	CITATIONS
91	Cross-Linking of CD32 Induces Maturation of Human Monocyte-Derived Dendritic Cells Via NF- $\kappa$ B Signaling Pathway. <i>Journal of Immunology</i> , 2003, 170, 3963-3970.	0.8	55
92	Regulation of B-Cell Activation by Complement Receptors CD21 and CD35. <i>Current Pharmaceutical Design</i> , 2003, 9, 1849-1860.	1.9	28
93	Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2 $\alpha$ BCR co-ligation is selective for the co-ligating antigen. <i>International Immunology</i> , 2002, 14, 241-247.	4.0	26
94	Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes. <i>Journal of Immunology</i> , 2002, 168, 2782-2788.	0.8	85
95	Bone marrow $\alpha$ derived mast cell differentiation is strongly reduced in histidine decarboxylase knockout, histamine $\alpha$ free mice. <i>International Immunology</i> , 2002, 14, 381-387.	4.0	29
96	Mucosal type mast cells express complement receptor type 2 (CD21). <i>Immunology Letters</i> , 2002, 82, 29-34.	2.5	12
97	Characterization of factor H-related cell membrane molecules expressed by human B lymphocytes and neutrophil granulocytes. <i>Immunology Letters</i> , 2001, 77, 55-62.	2.5	2
98	Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. <i>European Journal of Immunology</i> , 2000, 30, 1706-1713.	2.9	27
99	Bacterially expressed human Fc $\gamma$ RIIb is soluble and functionally active after in vitro refolding. <i>Immunology Letters</i> , 2000, 75, 33-40.	2.5	4
100	Immunomodulatory functions of murine CR1/2. <i>Immunopharmacology</i> , 2000, 49, 117-124.	2.0	27
101	H1 histamine receptor antagonist inhibits constitutive growth of Jurkat T cells and antigen-specific proliferation of ovalbumin-specific murine T cells. <i>Seminars in Cancer Biology</i> , 2000, 10, 41-45.	9.6	32
102	Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies. <i>Immunopharmacology</i> , 1999, 42, 159-165.	2.0	29
103	Inhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the Fc $\gamma$ RI. <i>Immunology Letters</i> , 1999, 68, 79-82.	2.5	15
104	HIV-1 induces human monocyte-derived macrophages to produce C3 and to fix C3 on their surface. <i>Journal of Leukocyte Biology</i> , 1998, 63, 463-468.	3.3	4
105	Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. <i>Aids</i> , 1997, 11, 949-958.	2.2	39
106	Complement peptides and mast cell triggering. <i>Immunology Letters</i> , 1996, 54, 109-112.	2.5	17
107	Complement peptide C3a inhibits IgE-mediated triggering of rat mucosal mast cells. <i>International Immunology</i> , 1995, 7, 1433-1439.	4.0	21
108	A novel, complement factor H-related regulatory protein expressed on the surface of human B cell lines. <i>European Journal of Immunology</i> , 1994, 24, 867-872.	2.9	10

#	ARTICLE	IF	CITATIONS
109	Cold target competition analysis of the classical activation pathway of complement-mediated cytotoxicity: A non-interaction model for competing lysis. <i>Molecular Immunology</i> , 1992, 29, 1347-1355.	2.2	5
110	Macrophage-Bound C3 Fragments as Adhesion Molecules Modulate Presentation of Exogenous Antigens. <i>Immunobiology</i> , 1992, 185, 314-326.	1.9	20
111	Novel regulators of the humoral immune response. <i>Trends in Immunology</i> , 1992, 13, A4-A6.	7.5	1
112	Complement research: biosynthesis, genetics, immunoregulatory role and clinical studies. <i>Trends in Immunology</i> , 1992, 13, A10-A12.	7.5	56
113	The role of C3 in the immune response. <i>Trends in Immunology</i> , 1991, 12, 332-337.	7.5	123
114	Characterization of the interleukin 5-reactive splenic B cell population. <i>European Journal of Immunology</i> , 1990, 20, 1949-1956.	2.9	19
115	Interaction between C3 and IL-2; inhibition of C3b binding to CR1 by IL-2. <i>Immunology Letters</i> , 1989, 21, 131-137.	2.5	8
116	Reversible biotinylation of C1q with a cleavable biotinyl derivative. <i>Journal of Immunological Methods</i> , 1988, 110, 251-260.	1.4	43
117	Appearance of acceptor-bound C3b on HLA-DR positive macrophages and on stimulated U937 cells; Inhibition of Fc $\gamma$ 3-receptors by the covalently fixed C3 fragments. <i>Molecular Immunology</i> , 1988, 25, 295-303.	2.2	19
118	The C1q receptor. <i>Molecular Immunology</i> , 1988, 25, 1067-1073.	2.2	33
119	Effector or target cell selection mediated by C3 bridges. <i>Immunology Letters</i> , 1987, 14, 243-248.	2.5	3
120	Cell cycle control of activated, synchronized murine B lymphocytes – roles of macrophages and complement C3. <i>Molecular Immunology</i> , 1986, 23, 1173-1176.	2.2	15
121	Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. <i>Nature</i> , 1985, 317, 264-267.	27.8	251
122	Functional cooperation of C3b-acceptors, Fc $\gamma$ 3-receptors and cell-surface proteases on macrophages. <i>Immunology Letters</i> , 1985, 11, 141-146.	2.5	4
123	The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. <i>European Journal of Immunology</i> , 1985, 15, 184-188.	2.9	85
124	Modulation of Fc receptor mediated functions by split products of C3. <i>Molecular Immunology</i> , 1984, 21, 1205-1210.	2.2	6
125	Role of C3b receptors in the enhancement of interleukin-2-dependent T-cell proliferation. <i>Molecular Immunology</i> , 1984, 21, 1215-1221.	2.2	32
126	IgG-Fc receptors differ in sensitivity to primary amines. <i>Immunology Letters</i> , 1983, 6, 265-269.	2.5	1



#	ARTICLE	IF	CITATIONS
127	C3b Acceptors on macrophages: Inhibition of Fc $\gamma$ 3-receptor-mediated phagocytosis by acceptor-bound C3b. Immunology Letters, 1983, 6, 287-291.	2.5	6
128	The Fc receptor model of membrane cytoplasmic signalling. Molecular Immunology, 1982, 19, 1223-1228.	2.2	16
129	Differential effect of low molecular weight alcohols on the Con A stimulation of mouse spleen cells. Immunology Letters, 1982, 4, 305-309.	2.5	3
130	Immune-complex-induced transglut aminase activation: Its role in the Fc-receptor-mediated transmembrane effect on peritoneal macrophages. Molecular Immunology, 1981, 18, 633-638.	2.2	44
131	Interference of I $\gamma$ 2-microglobulin specific autoantibodies with EA-binding of human peripheral lymphocytes; Inhibition of B-cell and enhancement of T-lymphocyte Fc-receptors. Immunology Letters, 1981, 3, 215-220.	2.5	0
132	Complement-dependent inhibition of Fc receptors on human peripheral blood mononuclear cells: inhibition of the binding of aggregated IgG, soluble and particulate immune complexes. Immunology Letters, 1980, 1, 223-226.	2.5	5
133	Effect of binding of C3 and its fragments on the plasma membrane fluidity of lymphocytes. Immunology Letters, 1980, 2, 115-118.	2.5	2
134	Studies on the mechanism of the complement-mediated inhibition of the Fc and C3 receptors of B lymphocytes. Clinical Immunology and Immunopathology, 1977, 8, 367-376.	2.0	12
135	Functionally active C1 on the surface of human peripheral lymphocytes: Its role in the complement-mediated inhibition of the Fc receptor of B lymphocytes. Clinical Immunology and Immunopathology, 1976, 5, 377-387.	2.0	18